JP2008530222A5 - - Google Patents

Download PDF

Info

Publication number
JP2008530222A5
JP2008530222A5 JP2007556264A JP2007556264A JP2008530222A5 JP 2008530222 A5 JP2008530222 A5 JP 2008530222A5 JP 2007556264 A JP2007556264 A JP 2007556264A JP 2007556264 A JP2007556264 A JP 2007556264A JP 2008530222 A5 JP2008530222 A5 JP 2008530222A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007556264A
Other languages
Japanese (ja)
Other versions
JP5063366B2 (ja
JP2008530222A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/005367 external-priority patent/WO2006088972A2/en
Publication of JP2008530222A publication Critical patent/JP2008530222A/ja
Publication of JP2008530222A5 publication Critical patent/JP2008530222A5/ja
Application granted granted Critical
Publication of JP5063366B2 publication Critical patent/JP5063366B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2007556264A 2005-02-16 2006-02-16 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 Expired - Fee Related JP5063366B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65347905P 2005-02-16 2005-02-16
US60/653,479 2005-02-16
PCT/US2006/005367 WO2006088972A2 (en) 2005-02-16 2006-02-16 Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011264338A Division JP5852426B2 (ja) 2005-02-16 2011-12-02 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用

Publications (3)

Publication Number Publication Date
JP2008530222A JP2008530222A (ja) 2008-08-07
JP2008530222A5 true JP2008530222A5 (enExample) 2008-11-20
JP5063366B2 JP5063366B2 (ja) 2012-10-31

Family

ID=36917026

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007556264A Expired - Fee Related JP5063366B2 (ja) 2005-02-16 2006-02-16 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用
JP2011264338A Expired - Fee Related JP5852426B2 (ja) 2005-02-16 2011-12-02 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用
JP2014111127A Expired - Fee Related JP6073833B2 (ja) 2005-02-16 2014-05-29 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用
JP2016183644A Expired - Fee Related JP6250764B2 (ja) 2005-02-16 2016-09-21 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011264338A Expired - Fee Related JP5852426B2 (ja) 2005-02-16 2011-12-02 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用
JP2014111127A Expired - Fee Related JP6073833B2 (ja) 2005-02-16 2014-05-29 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用
JP2016183644A Expired - Fee Related JP6250764B2 (ja) 2005-02-16 2016-09-21 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用

Country Status (7)

Country Link
US (6) US7968091B2 (enExample)
EP (3) EP2335719B1 (enExample)
JP (4) JP5063366B2 (enExample)
CA (1) CA2597925A1 (enExample)
ES (2) ES2547866T3 (enExample)
HK (1) HK1218875A1 (enExample)
WO (1) WO2006088972A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4986370B2 (ja) 2000-12-22 2012-07-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｒｇｍおよびそのモジュレーターの用途
CA2448382C (en) * 2001-05-25 2013-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin as a regulator of iron homeostasis
ES2551852T3 (es) 2004-07-23 2015-11-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
US7968091B2 (en) * 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
US20070099245A1 (en) * 2005-09-29 2007-05-03 Boris Gorovits Assays for neutralizing antibodies
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EA201692543A1 (ru) 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
EP2468291B1 (en) 2006-12-18 2017-11-22 Acceleron Pharma, Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CA3039330C (en) 2007-02-09 2021-11-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
US8895002B2 (en) 2007-04-09 2014-11-25 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP5922928B2 (ja) 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを高めるためのｇｄｆトラップの使用
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP2349332B1 (en) * 2008-11-13 2019-10-23 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation bmp-6
US20110293526A1 (en) * 2008-11-20 2011-12-01 University Of Southern California Compositions and methods to modulate hair growth
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
EP2665752B1 (en) 2011-01-19 2018-10-10 Ferrumax Pharmaceuticals, Inc. Compositions for regulating iron homeostasis and methods of using same
JP6336397B2 (ja) * 2011-12-14 2018-06-06 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 鉄関連障害を診断および治療するための組成物および方法
WO2013090635A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
PE20190907A1 (es) 2012-01-27 2019-06-26 AbbVie Deutschland GmbH and Co KG Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
JP6501362B2 (ja) * 2012-11-01 2019-04-17 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア エリスロフェロンおよびｅｒｆｅポリペプチドならびに鉄代謝を調節する方法
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
AR093620A1 (es) 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
US20160051556A1 (en) * 2013-03-21 2016-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
EP3008465B1 (en) * 2013-06-13 2019-08-07 Biodesy, Inc. Method of screening candidate biochemical entities targeting a target biochemical entity
AU2015274277B2 (en) 2014-06-13 2021-03-18 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
SMT202300166T1 (it) 2014-12-03 2023-07-20 Celgene Corp Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
EP3237906B8 (en) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
WO2016201077A1 (en) 2015-06-12 2016-12-15 Emory University Growth and survival compositions for cells capable of producing antibodies and methods related thereto
EP3344660B1 (en) 2015-08-31 2025-03-05 National Research Council of Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
JP6810988B2 (ja) * 2015-10-23 2021-01-13 ヴィフォール （インターナショナル） アクチェンゲゼルシャフトＶｉｆｏｒ （Ｉｎｔｅｒｎａｔｉｏｎａｌ） ＡＧ 新規なフェロポーチン阻害剤
CA3054135A1 (en) 2016-02-22 2017-08-31 Brigham Young University Method and compositions for the treatment of anemia through the inhibition of furin
CN110381988A (zh) 2016-06-15 2019-10-25 诺华股份有限公司 使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
EP3589663A4 (en) 2017-03-02 2020-10-21 National Research Council of Canada TGF-ß RECEPTOR ECTODOMAIN FUSION MOLECULES AND THEIR USES
US11125757B2 (en) 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
JP7504880B2 (ja) 2018-10-26 2024-06-24 ケロス セラピューティクス インコーポレイテッド Ａｌｋ２阻害剤の結晶形
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
WO2021062171A1 (en) * 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating anemia of chronic disease
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098821A1 (en) * 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating lymphopenia
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0414297B1 (en) 1989-08-11 1996-10-16 Gist-Brocades N.V. Efficient production of mutant proteases
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
WO1994024314A1 (en) 1993-04-19 1994-10-27 Kauffman Stuart A Random chemistry for the generation of new compounds
NZ276860A (en) 1993-11-02 1997-09-22 Affymax Tech Nv Apparatus and its use for synthesising diverse molecular products on substrates
AU6267098A (en) 1997-02-05 1998-08-25 Regents Of The University Of California, The Morphogenic proteins
EP1130094A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Primers for synthesizing full length cDNA clones and their use
CA2396719A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. 22 human secreted proteins
WO2002077006A1 (en) 2001-03-23 2002-10-03 Human Genome Sciences, Inc. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6800455B2 (en) 2000-03-31 2004-10-05 Scios Inc. Secreted factors
CN1159063C (zh) * 2000-06-21 2004-07-28 中国医学科学院血液学研究所 骨形态发生蛋白（bmp）作为治疗急性再生障碍性贫血药物的应用
JP4986370B2 (ja) 2000-12-22 2012-07-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｒｇｍおよびそのモジュレーターの用途
CA2448382C (en) 2001-05-25 2013-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin as a regulator of iron homeostasis
WO2003000461A1 (fr) 2001-06-21 2003-01-03 Meiyu-Giken Co., Ltd. Procede de polissage de la surface d'extremite de connexion d'un connecteur a fibres optiques, structure optique et structure heterogene coaxiale de couches de materiau, et dispositif de polissage
US20040248249A1 (en) 2001-07-05 2004-12-09 Tran Uyen K Secreted proteins
JP2003135075A (ja) 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
AU2003234136A1 (en) 2002-04-18 2003-11-03 The General Hospital Corporation Drg11-responsive (dragon) gene family
WO2004003150A2 (en) 2002-06-26 2004-01-08 Yale University Modulators and modulation of the interacton between rgm and neogenin
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
EP2006298A3 (en) 2003-04-15 2009-04-22 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
US20070184052A1 (en) * 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
US7968091B2 (en) * 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
CA2549477A1 (en) 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin

Similar Documents

Publication Publication Date Title
JP2008530222A5 (enExample)
BR122016023444A2 (enExample)
CH2121272H1 (enExample)
AT504380A8 (enExample)
CN300725936S (zh) 童装(3850)
CN300730999S (zh) 果汁机(sgl7003)
CN300728108S (zh) 电动跑步机(tr5100)
CN300730940S (zh) 电吹风(hz-5125)
CN300728027S (zh) 玩具(飞马套装43820)
CN300727930S (zh) 挂毯(28)
CN300725912S (zh) 童装(3706)
CN300727890S (zh) 图谱(世界海洋鱼类 10)
CN300726863S (zh) 硬质合金圆锯片包装盒(博深精品)
CN300726716S (zh) 锯片的切削端
CN300725944S (zh) 童装(3890)
CN300725943S (zh) 童装(3876)
CN300725942S (zh) 童装(3874)
CN300725941S (zh) 童装(3872)
CN300725940S (zh) 童装(3870)
CN300725933S (zh) 童装(3831)
CN300725913S (zh) 童装(3712)
CN300725938S (zh) 童装(3854)
CN300725937S (zh) 童装(3852)
CN300725914S (zh) 童装(3714)
CN300732181S (zh) 包装袋（粒粒香汤精）